Naglazyme® ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 19 | ライソゾーム病 | 1 |
19. ライソゾーム病
臨床試験数 : 854 / 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02156674 (ClinicalTrials.gov) | January 26, 2016 | 3/6/2014 | Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome | Study of Administration of Intravenous Naglazyme® Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome | Maroteaux-Lamy Syndrome | Drug: Naglazyme® | Masonic Cancer Center, University of Minnesota | BioMarin Pharmaceutical | Active, not recruiting | 3 Years | N/A | All | 1 | N/A | United States |